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Rachael E. Hawtin1* and Alessandra Cesano2Description of the technology
Understanding a patients’ immune status not only from
immune cell phenotyping, but also through analysis of
functional signaling capacity, enables the generation of a
more comprehensive understanding of the complex
mechanisms responsible for immunological tolerance in
cancer, and generates data that is complementary to
other non-functional phenotypic data sets such as im-
munohistochemical profiling and genomic analyses. Sin-
gle cell network profiling (SCNP) is a technology that
quantifies functional immune signaling capacity and
connectivity at a systems biology level. The technology
is based on multiparametric flow cytometry that simul-
taneously quantifies in multiple and rare immune cell
subsets, without the need for physical separation, both
extracellular surface markers and changes in intracellular
signaling proteins in response to extracellular modula-
tors. Quantifying modulated signaling across a panel of
modulators (e.g., IFNα, IFNγ, IL-4, IL-10, IL-27, anti-
CD3 etc.) and intracellular signaling pathways identifies
the functional capacity of the signaling network which
cannot be assessed by measuring basal (unmodulated)
signaling alone. A signaling node is defined as the com-
bination of the extracellular modulator with the intracel-
lular readout. For example TLR4 - > p-Erk defines one
signaling node in which TLR4 modulation is quantified
through the increase in p-Erk levels as compared to the
unmodulated reference. Typically 3 nodes are captured
simultaneously per well across multiple immune cell
subsets of interest (e.g., TLR4 - > p-Erk, p-S6, IkB).
The application of SCNP to clinical decision-making
requires the generation of high-content SCNP assays
with robust, accurate, quantifiable and reproducible re-
sults across time, operators and instruments. Each of the
procedural steps associated with an SCNP assay, includ-
ing pre-analytical sample handling, assay execution and* Correspondence: rachael.hawtin@nodality.com
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creativecommons.org/publicdomain/zero/1.0/reagents, data acquisition and analysis and the gener-
ation of metrics, have been validated [1] (Figs. 1 and 2).
Experimental assay setup is performed using propri-
etary software which enables experimental design/96-
well plate layouts and data capture to be contiguously
linked, ensuring that data from each well is correctly
assigned. The laboratory execution can be performed on
as many as 30 samples assayed for up to 40 wells (approxi-
mately 200–500 SCNP dimensions comprising modulator/
inhibitor/intracellular readout/cell subset combinations) in
2 to 3 days depending on the kinetic time points. A statis-
tical analysis plan (SAP) is drafted for all studies beyond the
exploratory phase, based upon clearly stated objec-
tives. For the identification of clinically validated clas-
sifiers the time frame for assay development and
validation is comparable to that of other technologies
(e.g., genomics, IHC) due to the requirements for stat-
istical powering and for verification and validation in
independent sample sets.Type of data obtained/readout
Currently the use of 10 cytometer channels is routine,
which includes 8 colors plus forward and side scatter.
The biological reads labeled per well can be expanded by
combining in one channel markers that are mutually ex-
clusively expressed on immune cells, for example CD4
and CD20. SCNP further increases dimensionality of
data obtained per sample via multiplexing as illustrated
in Fig. 1, using controls for both assay and cytometer
performance. Raw data (median fluorescence intensities)
are converted to calibrated metrics using control rain-
bow calibration particles on each 96-well plate. This al-
lows for normalization of readouts across 96 well plates,
across flow cytometry instruments, and for the same in-
strument over time. Captured data includes quantifica-
tion of cell subset frequencies and specific intracellular
readouts for each of the cell subsets in both the basal
(unmodulated) and modulated state. In addition, various
aspects of modulated signaling in each cell subset, and/
or signaling inhibition by in vitro drug exposure, areccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 SCNP Process. The SCNP process is coordinated from sample collection through to data analysis and visualization. Sample collection requires
standard sample draw into sodium-heparin coated tubes and overnight shipment at ambient temperature. Reagents and methods for the laboratory
assay are qualified and controlled for research, GxP or CLIA use as appropriate. The laboratory assay is controlled and multiplexed across 96 well plates
to enable broad biological analysis of each donor sample, with normalization across plates, instruments and time. A custom informatics infrastructure
ensures reliable and efficient data tracking and maintenance of data integrity. Multiple metrics are established for analysis of signaling magnitude, cell
population-based responses and signaling inhibition
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data for cells subject to different conditions. The “Fold”
metric is applied to measure magnitude of the respon-
siveness of a signal in a specific cell population relative
to the unmodulated reference. The proportion of a cell
population that is responsive to modulation is measured
by the Uu (rank based metric based on Mann–Whitney
U statistic) metric. Similarly, inhibited signaling is captured
using both magnitude and population-based metrics.
For each study, node metric comma separated value
(CSV) data files are generated which capture signaling
across cell subsets, linked with the complete meta data
annotations. These data can be integrated with data
from other platforms as appropriate and analyzed using
standard statistical tools. Analyses can address multiple
objectives including the development of multi-variate
predictors of response or prognosis, clustering, quantifica-
tion of signaling network function, quantification of drug
activity across nodes and immune cell subsets (includingIC50 determination). More comprehensive and interactive
mining of these multidimensional data sets is enabled via
an interactive web-based data portal (Fig. 2, concept dem-
onstrated as a video in [2]). The data portal enables online
data analysis and visualization, with associated statistical
annotations.
Limitations of the approach
SCNP requires live cells in suspension, and therefore is
not amenable to analysis of immune cells in flash frozen
or FFPE tissue samples. While broad profiling of signal-
ing per sample has been enabled by multiplexing and an
extensive array of biology has been established using this
technology, the assay is dependent upon the availability
of antibodies suitable for flow cytometry. Analysis of im-
mune signaling associated with antigen specificity has
not been established. It remains to be seen whether the
technology can be transferred to tumor cells isolated
from solid tissue.
Fig. 2 Data analysis. The cloud-based SCNPDataPortal enables investigator analysis of the data set in an interactive manner. Individual web pages
present data that address the specific objectives for each study. In the example shown these pages enable the analysis of; disease compared to
healthy donor signaling; interrogation of the mechanism of action (MOA) of a candidate molecule or therapeutic; analysis of biomarkers for
pharmacodynamic studies, patient selection / stratification and / or toxicity. Visualization options include heatmaps providing an overview of
the data and serving as a platform for deeper data mining. Parallel plots provide a means to identify donor subgroups, with each line representing a donor
sample with the associated signaling across multiple nodes and cell subsets. In the example shown, two donor subgroups are identified by
analysis of signaling in 3 node/cell subset combinations. Box-and-whisker plots enable the comparison of the range of signaling between
donor subgroups for selected nodes/cell subsets, with the coloring of each donor data point based upon demographic or clinical criteria. In
the example shown, signaling is compared in disease vs. healthy donor samples, with color coding for African American (blue) or caucasian
(red) donor samples. Clicking on the individual donor data enables interrogation of the single cell distributions for each data point
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One of the major advantages of this technology in the con-
text of immuno-oncology is the ability to monitor cellular
functional capacity without physical cell isolation. This en-
ables the detection and monitoring of immune signaling
and communication within the complex and interlocked
immune system. Interrogating the frequency and signaling
capacity of immune cells, and the effects of targeted thera-
peutics following either clinical administration or in vitro
exposure, can inform on disease and drug mechanism,
combination strategies, and identify biomarkers for
pharmacodymanic or patient stratification that are
otherwise inaccessible using less sensitive or non-
functional analyses [3–15]. The standardization of theSCNP process, combined with the ability to interrogate
signaling in rare cell subsets enables the quantification
of clinically relevant yet subtle signaling shifts that
would be otherwise undetectable using cell-averaging
approaches, or technologies which are not highly stan-
dardized or reproducible.
Types of samples needed and special issues
pertaining to samples
Appropriate pre-analytic sample manipulation is crucial.
SCNP has been used successfully with whole blood,
PBMC, BMMC [1] lamina propria mononuclear cells
isolated from human gut tissue, pleural fluids and blad-
der washings. Sample handling procedures are consistent
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sodium heparin coated tubes, shipment at ambient
temperature and processing using Ficoll separation, typ-
ically within 24 h of sample draw [16].
Level of evidence
Over 30 manuscripts and 70 abstracts have been pub-
lished using this platform. The analytic and clinical val-
idity is presented in many of these, with example
references below [1, 3–16]. The assay is conducted as
appropriate in a Research, GLP/GMP or CLIA certified
laboratory. Clinically validated classifiers for the predic-
tion of response/non response to standard induction
therapy in front line AML in both the elderly and
pediatric populations have been generated [3, 4]. Suc-
cessful application of SCNP to multiple stages of drug
development has been reported, encompassing mechan-
istic studies on molecules in early development through
to therapeutics in clinical development or use [13–15].
Signaling in primary patient samples from metastatic
melanoma, AML, CLL, MDS, rheumatoid arthritis (RA)
and systemic lupus erythematosus (SLE) donors is rou-
tinely analyzed.
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